JCI Insight (Mar 2021)

Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis

  • Jing Song,
  • Anja Schwenzer,
  • Alicia Wong,
  • Sara Turcinov,
  • Cliff Rims,
  • Lorena Rodriguez Martinez,
  • David Arribas-Layton,
  • Christina Gerstner,
  • Virginia S. Muir,
  • Kim S. Midwood,
  • Vivianne Malmström,
  • Eddie A. James,
  • Jane H. Buckner

Journal volume & issue
Vol. 6, no. 5

Abstract

Read online

Tenascin-C (TNC), an extracellular matrix protein that has proinflammatory properties, is a recently described antibody target in rheumatoid arthritis (RA). In this study, we utilized a systematic discovery process and identified 5 potentially novel citrullinated TNC (cit-TNC) T cell epitopes. CD4+ T cells specific for these epitopes were elevated in the peripheral blood of subjects with RA and showed signs of activation. Cit-TNC–specific T cells were also present among synovial fluid T cells and secreted IFN-γ. Two of these cit-TNC T cell epitopes were also recognized by antibodies within the serum and synovial fluid of individuals with RA. Detectable serum levels of cit-TNC–reactive antibodies were prevalent among subjects with RA and positively associated with cyclic citrullinated peptide (CCP) reactivity and the HLA shared epitope. Furthermore, cit-TNC–reactive antibodies were correlated with rheumatoid factor and elevated in subjects with a history of smoking. This work confirms cit-TNC as an autoantigen that is targeted by autoreactive CD4+ T cells and autoantibodies in patients with RA. Furthermore, our findings raise the possibility that coinciding epitopes recognized by both CD4+ T cells and B cells have the potential to amplify autoimmunity and promote the development and progression of RA.

Keywords